Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Jeffrey Skinner"'
Publikováno v:
Haematologica, Vol 100, Iss 12 (2015)
Externí odkaz:
https://doaj.org/article/12ce5e56783241ef8ca969447c2b2b22
Autor:
Jeffrey Skinner
“Once I walked a thin rail through a glacier” begins “Shattered Bio,” the first poem in Glaciology, Jeffrey Skinner's latest collection of poetry. Filled with images that slide into one another in a dreamlike way, from the “squeak of pine t
Autor:
Elias Jabbour, Koji Sasaki, Fadi G. Haddad, Ghayas C. Issa, Jeffrey Skinner, Sara Dellasala, Musa Yilmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip Thompson, Yesid Alvarado, Nitin Jain, Guillermo Garcia‐Manero, Koichi Takahashi, Gautam Borthakur, Naveen Pemmaraju, Sherry Pierce, Hagop Kantarjian
Publikováno v:
American Journal of Hematology. 97:1413-1418
Low-dose dasatinib is safe and effective in patients with chronic myeloid leukemia in chronic phase (CML-CP). No randomized trials have compared the outcome with standard-dose dasatinib. This study aims to compare the outcome of patients with CML-CP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e14dd64e4c555713d88ce2118484259
https://doi.org/10.1002/ajh.26689
https://doi.org/10.1002/ajh.26689
Autor:
Georgina Gener-Ricos, Fadi G. Haddad, Koji Sasaki, Ghayas C. Issa, Jeffrey Skinner, Lucia Masarova, Gautam Borthakur, Yesid Alvarado, Guillermo Garcia-Manero, Elias Jabbour, Hagop Kantarjian
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c866d36930d17f009057e627f244c569
https://doi.org/10.1016/j.clml.2023.05.009
https://doi.org/10.1016/j.clml.2023.05.009
Autor:
Elias Jabbour, Koji Sasaki, Ghayas C. Issa, Fadi Haddad, Guillermo Garcia-Manero, Tapan M. Kadia, William G. Wierda, Musa Yilmaz, Courtney D. DiNardo, Jeffrey Skinner, Naveen Pemmaraju, Sara E Dellasala, Sherry A. Pierce, Jorge E. Cortes, Hagop Kantarjian
Publikováno v:
Blood. 140:809-811
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c652e2a4ac2ef19a0bdbf16a864b5e43
https://doi.org/10.1182/blood-2022-169772
https://doi.org/10.1182/blood-2022-169772
Autor:
Georgina Gener-Ricos, Fadi Haddad, Koji Sasaki, Ghayas C. Issa, Jeffrey Skinner, Koichi Takahashi, Lucia Masarova, Jan A. Burger, Gautam Borthakur, Prithviraj Bose, Guillermo Garcia-Manero, Elias Jabbour, Hagop Kantarjian
Publikováno v:
Blood. 140:1493-1494
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3573567e0dbd089134d64e393376ef2a
https://doi.org/10.1182/blood-2022-167764
https://doi.org/10.1182/blood-2022-167764
Autor:
Alex Bataller, Koji Sasaki, Elias Jabbour, Ghayas C. Issa, Fadi Haddad, Jeffrey Skinner, Sara E Dellasala, Guillermo Garcia-Manero, Sherry A. Pierce, Hagop Kantarjian
Publikováno v:
Blood. 140:3895-3896
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84be8f3e837312aa05c98bb6d6d64a1f
https://doi.org/10.1182/blood-2022-164924
https://doi.org/10.1182/blood-2022-164924
Autor:
Tapan M. Kadia, Guillermo Garcia-Manero, Musa Yilmaz, Ghayas C. Issa, Rita Khouri, Patrice Nasnas, Hagop M. Kantarjian, Sara Dellasala, Sherry Pierce, Courtney D. DiNardo, Jorge E. Cortes, William G. Wierda, Naveen Pemmaraju, Koji Sasaki, Jeffrey Skinner, Elias Jabbour
Publikováno v:
Blood. 136:42-44
Background: Tyrosine kinase inhibitors (TKI) improve survival in patients with chronic myeloid leukemia in chronic phase (CML-CP), who meet molecular milestones at specific timepoints. The European LeukemiaNet (ELN) revised the recommendations of mol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39c85e435ae7ff62fe890abcce9d35eb
https://doi.org/10.1182/blood-2020-143023
https://doi.org/10.1182/blood-2020-143023
Autor:
Jan A. Burger, Prithviraj Bose, Nitin Jain, Musa Yilmaz, Sherry Pierce, Kiran Naqvi, Sara Dellasala, Koichi Takahashi, Philip A. Thompson, Rita Khouri, Hagop M. Kantarjian, Koji Sasaki, Elias Jabbour, Jeffrey Skinner, Jorge E. Cortes, Naveen Pemmaraju, Guillermo Garcia-Manero, Alessandra Ferrajoli, Gautam Borthakur, Kristin Anderson, Yesid Alvarado, Shilpa Paul
Publikováno v:
Blood. 136:3-5
Background: Low-dose dasatinib was shown to be safe and effective in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). There is no randomized clinical trials to compare the outcome with the standard-dose dasatinib. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51b29b2f8de8fbb107acbe9fe2c8bf00
https://doi.org/10.1182/blood-2020-140003
https://doi.org/10.1182/blood-2020-140003
Autor:
Kristin Anderson, Hagop M. Kantarjian, Jorge E. Cortes, Zeev Estrov, Musa Yilmaz, Alessandra Ferrajoli, Naveen Pemmaraju, Kiran Naqvi, Yesid Alvarado, Sara Dellasala, Prithviraj Bose, Philip A. Thompson, Gautam Borthakur, Jan A. Burger, Nitin Jain, Elias Jabbour, Koichi Takahashi, Jeffrey Skinner, Shilpa Paul
Publikováno v:
Cancer
Background Dasatinib, a potent Bcr-Abl tyrosine kinase inhibitor, is approved for the treatment of chronic-phase chronic myeloid leukemia (CML-CP) in the frontline and salvage settings. Notable side effects include pleural effusions and myelosuppress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a576fbf8b63412a684684ddcfbd2d393
https://doi.org/10.1002/cncr.32504
https://doi.org/10.1002/cncr.32504